Abstract
Objective: To investigate a novel therapeutic approach for Charchot-Marie-Tooth disease type 2A (CMT2A) using RNAi/gene therapy combination.
Background: CMT2A is a rare inherited axonal peripheral neuropathy caused by mutations in the mitofusin 2 (MFN2) gene and characterized by progressive distal muscle weakness, atrophy, sensory loss, and normal or near-normal nerve conduction velocities. MFN2 mutations have been characterized and numerous mechanisms proposed to unravel CMT2A pathophysiology; however, no cure for this devastating disease is available. Thus, it is crucial to identify a treatment to cure or at least mitigate CMT2A progression.
Design/Methods: Our proposed approach combined RNA interference (RNAi) with gene therapy as therapeutic strategy for CMT2A. In induced pluripotent stem cells (iPSCs) obtained from CMT2A patients we targeted the MFN2 mutant allele with specific short hairpin RNAs (shRNAs) and simultaneously introduced a mutagenized MFN2 gene able to be resistant to shRNA activity and still encoding the native protein. We then differentiated iPSCs into spinal motor neurons (MNs) and analyzed the sub-cellular parameters we previously found to be altered in CMT2A in vitro model (Rizzo et al., 2016) were evaluated to assess the impact of our therapy.
Results: We successfully silenced endogenous MFN2 gene and restored functional MFN2 protein level in CMT2A cells without altering iPSC pluripotency. In addition, MNs differentiated from both treated and untreated CMT2A iPSCs showed typical MN morphology and expressed the main MN markers. Qualitative and quantitative alterations characteristic of CMT2A disease (Rizzo et al., 2016) were restored after our therapy in CMT2A MNs. Specifically, we observed an increase in mitochondria number, an improvement of mitochondrial axonal transport, re-established sensitivity to apoptosis and reduction of authophagy/mytophagy.
Conclusions: Overall, our results led to a significant level of rescue in CMT2A MNs, suggesting RNAi/gene therapy combined approach as a promising therapeutic strategy for CMT2A.
Disclosure: Dr. Rizzo has nothing to disclose. Dr. Bono has nothing to disclose. Dr. Salani has nothing to disclose. Dr. Bordoni has nothing to disclose. Dr. Melzi has nothing to disclose. Dr. Ruepp has nothing to disclose. Dr. Pagliarani has nothing to disclose. Dr. Barbullushi has nothing to disclose. Dr. Abati has nothing to disclose. Dr. Cordiglieri has nothing to disclose. Dr. Bresolin has nothing to disclose. Dr. Comi has nothing to disclose. Dr. Nizzardo has nothing to disclose. Dr. Corti has nothing to disclose.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
